HIV / AIDS
- Category: HIV Treatment
- Published on Tuesday, 05 December 2006 12:30
Interruption of antiretroviral therapy is a potentially hazardous strategy associated with an increased risk of disease progression or death, according to data from the large international SMART (Strategies for Management of Antiretroviral Therapy) study.
- Category: Liver & Kidney Disease
- Published on Tuesday, 14 November 2006 00:00
The Thomas E. Starzl Transplant Surgery State-of the-Art Lecture at this year’s American Association for the Study of Liver Diseases (AASLD) annual meeting was devoted to the outcomes following solid organ transplantation in HIV-infected recipients. The speaker, Peter G. Stock, MD, from the University of California at San Francisco, gave a very good update on the topic.
- Category: Experimental HIV Drugs
- Published on Friday, 25 August 2006 00:00
Data on several investigational anti-HIV drug candidates were presented at the XVI International AIDS Conference last week in Toronto, including the latest results from a study of Tanox’s investigational monoclonal antibody, TNX-355. TNX-355 is a recombinant human antibody that binds to domain 2 of the CD4 receptor, thereby blocking the entry of HIV into host cells.
- HIV Treatment
- HIV Prevention
- HIV Testing & Diagnosis
- HIV Disease Progression
- HIV-Related Conditions
- Side Effects - HIV
- HIV Basic Science
- HIV/AIDS Epidemiology & Mortality
- HIV Populations
- HIV Policy & Advocacy